98%
921
2 minutes
20
Bacteriophage therapy is considered one of the most promising tools to control zoonotic bacteria, such as , in broiler production. Phages exhibit high specificity for their targeted bacterial hosts, causing minimal disruption to the niche microbiota. However, data on the gut environment's response to phage therapy in poultry are limited. This study investigated the influence of phage on host physiology through caecal microbiota and metabolome modulation using high-throughput 16S rRNA gene sequencing and an untargeted metabolomics approach. We employed 24 caecum content samples and 24 blood serum samples from 4-, 5- and 6-week-old broilers from a previous study where phages were administered via feed in -infected broilers, which were individually weighed weekly. Phage therapy did not affect the alpha or beta diversity of the microbiota. Specifically, we observed changes in the relative abundance of 14 out of the 110 genera using the PLS-DA and Bayes approaches. On the other hand, we noted changes in the caecal metabolites (63 and 37 out of the 1113 caecal metabolites). Nevertheless, the minimal changes in blood serum suggest a non-significant physiological response. The application of phages under production conditions modulates the caecal microbiome and metabolome profiles in broilers without impacting the host physiology in terms of growth performance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607084 | PMC |
http://dx.doi.org/10.3390/ijms242015201 | DOI Listing |
Trends Microbiol
September 2025
Marine Biological Section, Department of Biology, University of Copenhagen, Helsingør, Denmark; HADAL & Nordcee, Department of Biology, University of Southern Denmark, Odense, Denmark. Electronic address:
As antimicrobial resistance threatens the future of the aquaculture industry, numerous studies have investigated the use of phages against aquaculture diseases over the past decades. Despite reports of efficient pathogen control, commercial phage solutions are sparse. We discuss limitations of phage therapy and provide suggestions for the progression towards commercially viable solutions.
View Article and Find Full Text PDFJ Control Release
September 2025
Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia; Materials Research Laboratory, University of California, Santa Barbara, CA 93106, USA. Electronic address:
Most chemotherapeutics distribute non-specifically throughout the body, resulting in off-target toxicities. Nanoparticle (NP) formulations provide a strategy to improve drug delivery by extending circulation time, protecting therapeutic agents from degradation, and enabling controlled release. However, delivering NPs effectively to solid tumors remains challenging due to the barriers within the tumor microenvironment.
View Article and Find Full Text PDFFood Res Int
November 2025
Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), 1068 Xueyuan Avenue, Shenzhen 518055, China. Electronic address:
Inflammatory bowel disease (IBD) encompasses two main conditions: Crohn's disease and ulcerative colitis. The role of foodborne pathogens, often transmitted through contaminated food, is a subject of ongoing research regarding their potential involvement in IBD. The most common foodborne pathogens S.
View Article and Find Full Text PDFInt J Antimicrob Agents
September 2025
Institute for Technology Assessment and Systems Analysis (ITAS), Karlsruhe Institute of Technology, P.O. Box 3640, 76021 Karlsruhe, Germany. Electronic address:
As antibiotic resistance of bacterial pathogens spreads, interest in bacteriophage (phage) therapy has soared again in many countries. Currently, there is no phage therapeutic with marketing approval and phage treatments are relegated to few patients, mostly under compassionate use schemes when approved drugs failed or are unavailable. Commercially manufactured and approved phage preparations could both expand the availability of therapeutic phages for existing, exemptional treatment schemes and result in more broadly usable phage therapeutics with marketing authorization.
View Article and Find Full Text PDFInt J Antimicrob Agents
September 2025
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Non-Traditional Antibacterial Therapy (ESGNTA); Phage Canada, Maple, Ontario, Canada; Unity Health Toronto,
With antimicrobial resistance as a worldwide public health concern, bacteriophage (phage) therapy (PT) may help treat bacterial infections. However, given its particularities compared with traditional small molecule drugs, there are variations in how it is regulated worldwide. Regulators are key players governing PT, yet their perspectives have been largely unexplored.
View Article and Find Full Text PDF